H.C. Wainwright reiterates Buy rating and $15 price target for Korro Bio after first cohort dosing
H.C. Wainwright reaffirmed a Buy rating on Korro Bio and set a $15.00 price target after the company dosed the initial cohort in its Phase 1/2 ANCHOR trial of KRRO-121. The biotech's shares were trading at $9.97, down 77% over the past year. The trial is planned to last about a year, and its primary completion is projected for the latter half of 2027. Korro Bio reported a current ratio of 9.55 and cash exceeding its debt.
Why it matters
The analyst’s price target implies roughly 50% upside from the current price, which may attract investors seeking upside in a cash‑rich biotech. The trial progress and strong balance sheet reduce financing risk for the upcoming study.
Key facts
- 1H.C. Wainwright reiterated a Buy rating on Korro Bio. investing.com
- 2The firm set a price target of $15.00 for the stock. investing.com
- 3Korro Bio dosed the first cohort in the Phase 1/2 ANCHOR trial for KRRO-121. investing.com
- 4The stock was trading at $9.97 at the time of the announcement. investing.com
- 5Shares had fallen 77% over the past year. investing.com
- 6The company’s current ratio was 9.55. investing.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.